LETTER FROM THE VICE CHAIRMANN
India has attracted several clinical research projects
in the last 5 years seeking quality data and speedy completion. Sites meeting
ICH-GCP guidelines, English speaking investigators and drug naïve patients
have enabled India to emerge as a key global destination for clinical research.
ECRON AcuNova has been entrusted with key trials involving recombinant drugs,
monoclonal antibodies and diagnostic agents. Global regulation has accepted
the research data produced by us and accorded approval to sponsors. Sponsors
have found supply chain management and Central Lab service by us particularly
useful in project management.
While we have served a wide spectrum of studies, our reputation has been particularly
high in phase II trials for bio pharma and phase II-III trials for diagnostics
and device companies. Many sponsors have opted for comprehensive services including
CDM and Bio Statistics.
We are encouraged by your response and have now opted to expand our forte in
the European and US market with our merger with ECRON GmbH, who brings on board
20 years of enriched experience in successfully bringing drugs into the market.
Today we have with us human capital of over 265 professionals and are adding
services like Bio Imaging and cardiac safety analysis which are becoming a mandate
by leading regulators.
We look forward to beginning as a new entity and compel you to look at the uniqueness
of our new relationship and embark on our journey with this new entity. We welcome
you to partner with us in bringing new drugs, therapies and devices to market
with innovation and speed.
D A Prasanna
Vice Chairman & Managing Director
Manipal AcuNova Ltd